Osteoarthritis Gene Therapy Market Size is valued at US$ 1.4 Bn in 2024 and is predicted to reach US$ 4.0 Bn by the year 2034 at an 11.7% CAGR during the forecast period for 2025-2034.
Gene therapy for osteoarthritis involves the direct delivery of therapeutic genes into affected joints. This approach aims to combat the disease on a molecular level by reducing inflammation, promoting cartilage regeneration, and slowing overall disease progression. By addressing underlying causes, gene therapy can provide long-lasting pain relief and significantly improve joint function.
As a disease-modifying treatment, this modality represents a new class of therapy that could potentially reduce the reliance on repeated steroid injections or eventual joint replacement surgery. It is being developed for osteoarthritis in various weight-bearing joints, including the knee and hip.Furthermore, gene therapy advances the field of personalized medicine, paving the way for tailored treatments based on a patient's unique genetic and molecular profile. Overall, it stands as a promising and transformative alternative to conventional pharmacological and surgical interventions.
The global market for Osteoarthritis Gene Therapy is expanding due to the increasing prevalence of osteoarthritis, which is another key factor driving the osteoarthritis gene therapy market. The rising prevalence of osteoarthritis assist market growth by creating demand for effective, long-term, minimally invasive treatments, motivating development and utilization of the superior effectiveness of gene therapies targeting the mechanisms of disease onset and progression.
Arthritis constitutes a major public health problem. The CDC estimates that 1 in 5 (or 53.2 million) US adults report some form of arthritis. Despite a high prevalence, the development of osteoarthritis gene therapy has obstacles to growth, including high development costs, complicated delivery routes, reimbursement and access issues. Throughout the duration of the forecast period, opportunities for the osteoarthritis gene therapy market will occur as the high incidence in the ageing population and obese populations increases, as well as advancements in targeted gene delivery, and an increase in funding will spur research development, clinical trials, and commercialisation.
Some of the Key Players in the Osteoarthritis Gene Therapy Market:
The osteoarthritis gene therapy market is segmented by therapeutic approach, type of therapy, administration route, and target molecule. By therapeutic approach, the market is segmented into gene editing, gene delivery, gene regulation, gene silencing, and gene replacement. By type of therapy, the market is segmented into autologous therapy and allogeneic therapy. By administration route, the market is segmented into intra-articular injection, systemic administration, and local administration. By target molecule, the market is segmented into cytokines, growth factors, proteins, enzymes, and micrornas.
The gene editing segment category led the osteoarthritis gene therapy market in 2024. This dominance is fueled by the ability to make targeted gene alterations to more accurately treat the underlying disease process, delivering long-term targeting therapeutic benefits. Gene editing can use tools like CRISPR-Cas9 and TALENs to modify molecular pathways involved in cartilage degeneration and the inflammatory process, relieving pain while decreasing dependency on ongoing symptomatic treatments and providing longer tangible benefits with delayed dementia modifying effects.
Notably, there is apparent commitment to continued research initiatives for osteoarthritis including the gene-editing method, enhanced development of and increase in novel delivery technologies, an influx of clinical studies examining gene-editing in patients with knee osteoarthritis, and its efficient, more animal and human specific, ability to progressively treat osteoarthritis in a way that fits with modern principles/initiatives of precision medicine allows gene editing to be the preferred global therapeutic approach.
The largest and fastest-growing type of therapy is autologous therapy, as it utilizes a patient’s own cells. This eliminates immune rejection and enhances safety; hence, it can provide individualised, targeted treatment for the repair of cartilage, the reduction of inflammation, and the regeneration of joints.
The increasing clinical success and positive patient responses enhance the rate of adoption by both clinicians and patients alike. Moreover, autologous therapies are in line with regulatory agency preferences for safer, more personalized treatment options and increasingly supported by investment in health care and clinical studies. The ease of use with minimally invasive therapies and the promise of long-term effectiveness also reinforce its preeminence over allogeneic and other types of therapies.
North america dominated the osteoarthritis gene therapy market in 2024. The united states is at the forefront of this expansion. This is due to a well-established healthcare system, an early and strong acceptance of advanced biotechnologies, and an increase in investment related to regenerative medicine and clinical research.
In addition, the established presence of important pharmaceutical and biotechnology companies, relatively supportive regulatory environments, and high patient awareness and acceptance of innovative therapeutic options are other contributors to market leadership. Disease prevalence in the ageing population will also contribute to heightened demand for minimally invasive, disease-modifying therapies in the region.
With increasing investment in healthcare, growing biotechnology and regenerative medicine industries, and the continued rise of osteoarthritis in the asia-pacific area, the osteoarthritis gene therapy market is expanding at the strongest and fastest rate in this region. There is an increasing demand for innovative and cost-efficient therapies in countries. The rapid growth of the market in the region can also be attributed to the support of government initiatives to facilitate innovation, expand clinical trial infrastructures, and enhance patient awareness of gene therapy solutions.
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Osteoarthritis Gene Therapy Market Snapshot
Chapter 4. Global Osteoarthritis Gene Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Osteoarthritis Gene Therapy Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Osteoarthritis Gene Therapy Market Industry Trends
Chapter 5. Osteoarthritis Gene Therapy Market Segmentation 1: By Therapeutic Approach, Estimates & Trend Analysis
5.1. Market Share by Therapeutic Approach, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapeutic Approach:
5.2.1. Gene Editing
5.2.2. Gene Delivery
5.2.3. Gene Regulation
5.2.4. Gene Silencing
5.2.5. Gene Replacement
Chapter 6. Osteoarthritis Gene Therapy Market Segmentation 2: By Type of Therapy, Estimates &
Trend Analysis
6.1. Market Share by Type of Therapy, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following
Type of Therapy:
6.2.1. Autologous Therapy
6.2.2. Allogeneic Therapy
Chapter 7. Osteoarthritis Gene Therapy Market Segmentation 3: By Administration Route, Estimates & Trend Analysis
7.1. Market Share by Administration Route, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Administration Route:
7.2.1. Intra-Articular Injection
7.2.2. Systemic Administration
7.2.3. Local Administration
Chapter 8. Osteoarthritis Gene Therapy Market Segmentation 4: By Target Molecule, Estimates & Trend Analysis
8.1. Market Share by Target Molecule, 2024 & 2034
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Target Molecule:
8.2.1. Cytokines
8.2.2. Growth Factors
8.2.3. Proteins
8.2.4. Enzymes
Chapter 9. Osteoarthritis Gene Therapy Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Osteoarthritis Gene Therapy Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Therapeutic Approach, 2021-2034
9.2.3. North America Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Type of Therapy, 2021-2034
9.2.4. North America Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Administration Route, 2021-2034
9.2.5. North America Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Target Molecule, 2021-2034
9.3. Europe
9.3.1. Europe Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Therapeutic Approach, 2021-2034
9.3.3. Europe Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Type of Therapy, 2021-2034
9.3.4. Europe Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Administration Route, 2021-2034
9.3.5. Europe Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Target Molecule, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Therapeutic Approach, 2021-2034
9.4.3. Asia Pacific Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Type of Therapy, 2021-2034
9.4.4. Asia Pacific Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Administration Route, 2021-2034
9.4.5. Asia Pacific Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Target Molecule, 2021-2034
9.5. Latin America
9.5.1. Latin America Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Therapeutic Approach, 2021-2034
9.5.3. Latin America Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Type of Therapy, 2021-2034
9.5.4. Latin America Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Administration Route, 2021-2034
9.5.5. Latin America Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Target Molecule, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Therapeutic Approach, 2021-2034
9.6.3. Middle East & Africa Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Type of Therapy, 2021-2034
9.6.4. Middle East & Africa Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Administration Route, 2021-2034
9.6.5. Middle East & Africa Osteoarthritis Gene Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Target Molecule, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Flexion Therapeutics Inc.
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. GeneQuine Biotherapeutics
10.2.3. Novartis AG
10.2.4. Smith & Nephew
10.2.5. Genascence
10.2.6. Kolon TissueGene, Inc.
10.2.7. Sanofi
10.2.8. Parexel International Corporation
10.2.9. Medipost
10.2.10. Mundipharma
10.2.11. Cynata Therapeutics
10.2.12. Mestex AG
10.2.13. Rottapharm Biotech
10.2.14. Remedium Bio
10.2.15. Eli Lilly and Company
10.2.16. Kitware
Osteoarthritis Gene Therapy Market by Therapeutic Approach-
· Gene Editing
· Gene Delivery
· Gene Regulation
· Gene Silencing
· Gene Replacement
Osteoarthritis Gene Therapy Market by Type of Therapy-
· Autologous Therapy
· Allogeneic Therapy
Osteoarthritis Gene Therapy Market by Administration Route-
· Intra-Articular Injection
· Systemic Administration
· Local Administration
Osteoarthritis Gene Therapy Market by Target Molecule-
· Cytokines
· Growth Factors
· Proteins
· Enzymes
Osteoarthritis Gene Therapy Market by Region-
North America-
· The US
· Canada
Europe-
· Germany
· The UK
· France
· Italy
· Spain
· Rest of Europe
Asia-Pacific-
· China
· Japan
· India
· South Korea
· Southeast Asia
· Rest of Asia Pacific
Latin America-
· Brazil
· Argentina
· Mexico
· Rest of Latin America
Middle East & Africa-
· GCC Countries
· South Africa
· Rest of the Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
